Shares of Biocept Inc (NASDAQ:BIOC) gapped up prior to trading on Wednesday . The stock had previously closed at $0.67, but opened at $0.72. Biocept shares last traded at $0.71, with a volume of 375576 shares changing hands.

Several analysts have issued reports on BIOC shares. Zacks Investment Research raised Biocept from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Chardan Capital reissued a “buy” rating and issued a $1.50 price target (down previously from $2.50) on shares of Biocept in a research note on Tuesday, November 14th. Finally, ValuEngine raised Biocept from a “strong sell” rating to a “sell” rating in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $2.25.

The firm has a market cap of $21.86, a price-to-earnings ratio of -0.81 and a beta of 2.77. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.27 and a current ratio of 1.41.

A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. grew its stake in Biocept Inc (NASDAQ:BIOC) by 9.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 764,351 shares of the medical research company’s stock after acquiring an additional 66,746 shares during the period. Vanguard Group Inc. owned 2.87% of Biocept worth $1,048,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.